About this journal
Aims and scope
Cell Cycle is a bi-weekly peer-reviewed journal of high priority research from all areas of cell biology.
Cell Cycle covers all topics from yeast to man, from DNA to function, from development to aging, from stem cells to cell senescence, from metabolism to cell death, from cancer to neurobiology, from molecular biology to therapeutics. Our goal is fast publication of outstanding research. Cell Cycle accepts the following types of article: Research Papers/Reports, Reviews, Perspectives, Letters to the Editor and News and Views.
Cell Cycle has a prominent Editorial Board, which includes 3 Nobel Prize winners and other outstanding scientists.
Categories of manuscripts include:
-
Research papers/Reports
-
Perspectives/Reviews
-
Invited follow-ups to important articles published in Cell Cycle and elsewhere: Extra Views, Features, News and Views
Please note that this journal only publishes manuscripts in English.
Cell Cycle offers online manuscript submission and single anonymized peer-review by independent, anonymous expert referees, as well as a flexible open access policy.
The journal is indexed by PubMed/Medline, Thomson Reuters, and Scopus. It is available both in the print and online formats.
Cell Cycle will, at the discretion of the Chief Editor, consider reviewer reports from previous submission to other high-impact journals for accelerated review. High-priority papers will be peer-reviewed and published as soon as possible.
Authors can choose to publish gold open access in this journal.
Journal metrics
Usage
- 1.3M annual downloads/views
Citation metrics
- 3.4 (2023) Impact Factor
- 4.4 (2023) 5 year IF
- 7.7 (2023) CiteScore (Scopus)
- Q1 CiteScore Best Quartile
- 0.672 (2023) SNIP
- 0.947 (2023) SJR
Speed/acceptance
- 72 days avg. from submission to first decision
- 85 days avg. from submission to first post-review decision
- 12 days avg. from acceptance to online publication
- 29% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief
Michael Lisanti
University of Salford
Manchester, UK
Founding Editor-in-Chief
Mikhail V. Blagosklonny
Roswell Park Cancer Institute
Buffalo, NY, US
Assistant to Editor-in-Chief
Yelena P. Boryskina
Institute of Radiophysics and Electronics NASU
Kharkov, UA
[email protected]
Associate Editors
Chris Albanese - Georgetown University, Washington, DC, US
Eleonora Candi - University of Rome "Tor Vergata", Rome, Italy
Luigi Donato - Università degli Studi di Messina, Italy
Stefano Falone - University of L'Aquila, L'Aquila, Italy
Giuseppe Nicolò Fanelli - University of Pisa, Italy
Ubaldo Martinez-Outschoorn - Kimmel Cancer Center, Philadelphia, US
Ndabezinhle Mazibuko - King's College London, London, UK
Erika Maria Parasido - Georgetown University, Washington, DC, US
Cristian Scatena - University of Pisa, Italy
Federica Sotgia - University of Salford, UK
Editorial Board
Frederick W. Alt - Children's Hospital, Boston, MA, US
Jiri Bartek - Danish Cancer Society, Copenhagen, DK
John Blenis - Weill Cornell Medicine, New York, NY, US
Judith Campisi - Buck Institute for Research on Aging, Novato, CA, US
Lewis Cantley - Weill Cornell Medicine, New York, NY, US
Duncan J. Clarke - University of Minnesota Medical School, Minneapolis, MN, US
Bruce E. Clurman - Fred Hutchinson Cancer Research Center, Seattle, WA, US
Carlo M. Croce - The Ohio State University, Columbus, OH, US
Zbigniew Darzynkiewicz - New York Medical College, Vallhalla, NY, US
Ronald A. DePinho - The University of Texas MD Anderson Cancer Center, Houston, TX, US
Julian Downward - Francis Crick Institute, London, UK
Brian J. Druker - Oregon Health Science University, Portland, OR, US
Wafik S. El-Deiry - Warren Alpert Medical School, Brown University, Providence, Rhode Island, US
Stephen J. Elledge - Harvard Medical School, Boston, MA, US
Gerard Evan - University of Cambridge, Cambridge, UK
David E. Fisher - Massachusetts General Hospital, Boston, MA, US
Tito Fojo - Columbia University, New York, NY, US
Douglas Green - St. Jude Children's Hospital, Memphis, TN, US
Andrei V. Gudkov - Roswell Park Cancer Institute, Buffalo, NY, US
Michael N. Hall - Biozentrum of the University of Basel, Basel, CH
Philip W. Hinds - Tufts University School of Medicine, Boston, MA, US
Tony Hunter - The Salk Institute, La Jolla, CA, US
Matt Kaeberlein - University of Washington, Seattle, WA, US
Brian K. Kennedy - National University of Singapore, SG
Daniel J. Klionsky - University of Michigan, Ann Arbor, MI, US
Eugene V. Koonin - National Institutes of Health, Bethesda, MD, US
Boris P. Kopnin - Blokhin Russian Cancer Research Center, Moscow, RU
Guido Kroemer - Gustave Roussy Comprehensive Cancer Insitute, Villejuif, FR
David P. Lane - Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), SG
Arnold Levine - Institute for Advanced Study, Princeton, NJ, US
Chiang J. Li - Harvard Medical School, Boston, MA, US
James A. McCubrey - East Carolina University, Greenville, NC, US
Gerry Melino - University of Rome Tor Vergata, Rome, IT
Yusuke Nakamura - Japanese Foundation for Cancer Research, Tokyo, JP
Mikhail A. Nikiforov - Wake Forest University Comprehensive Cancer Center, Winston-Salem, NC, US
Paul Nurse - Francis Crick Institute, London, UK
André Nussenzweig - National Institutes of Health, Bethesda, MD, US
Moshe Oren - Weizmann Institute of Science, Rehovot, IL
Helen Piwnica-Worms - The University of Texas MD Anderson Cancer Center, Houston, TX, US
George C. Prendergast - Thomas Jefferson University, Philadelphia, PA, US
Carol Prives - Columbia University, New York, NY, US
E. Premkumar Reddy - Icahn School of Medicine at Mount Sinai, New York, NY, US
John C. Reed - The Sandford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, US
Steven I. Reed - The Scripps Research Institute, La Jolla, CA, US
James M. Roberts - Fred Hutchinson Cancer Research Center, Seattle, WA, US
Igor B. Roninson - University of South Carolina, Columbus, US
Martine Roussel - St. Jude's Children's Hospital, Memphis, TN, US
Paolo Sassone-Corsi - University of California, Irvine, CA, US
Charles L. Sawyers - Memorial Sloan Kettering Cancer Center, New York, NY, US
John M. Sedivy - Brown University, Providence, RI, US
Andrei Seluanov - University of Rochester, Rochester, NY, US
Charles J. Sherr - St. Jude's Children's Hospital, Memphis, TN, US
Vladimir P. Skulachev - Moscow State University, Moscow, RU
Frank Slack - Harvard Medical School, Boston, MA, US
Alexander Shneider - CureLab Oncology, Inc., Boston, MA, US
Gary S. Stein - University of Vermont, Burlington, US
Qing-Yuan Sun - Chinese Academy of Sciences, Beijing, CN
George F. Vande-Woude - Van Andel Institute, Grand Rapids, MI, US
Bert Vogelstein - Johns Hopkins University, Baltimore, MD, US
Peter K. Vogt - The Scripps Research Institute, La Jolla, CA, US
Karen Vousden - The Francis Crick Institute, London, UK
Paul Workman - The Institute of Cancer Research, London, UK
Gen Sheng Wu - Wayne State University, Detroit, MI, US
Michael B. Yaffe - Massachusetts Institute of Technology, Cambridge, MA, US
Yi-Xin Zeng - Sun Yat-sen University Cancer Center, Guang Zhou, CN
Harald zur Hausen - Deutsches Krebsforschungszentrum, Heidelberg, DE
Abstracting and indexing
- Adis International Ltd.
- Reactions Weekly (Online) - Chemical Abstracts Service
- Chemical Abstracts (Online) - EBSCOhost
- Biological Abstracts (Online) - Elsevier BV
- BIOBASE
- EMBASE
- Scopus - National Library of Medicine
- PubMed Central (PMC) - Thomson Reuters
- Biological Abstracts (Online)
- BIOSIS Previews
- Current Contents
- Science Citation Index Expanded
- Web of Science - U.S. National Library of Medicine
- MEDLINE
Open access
Cell Cycle is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
24 issues per year
Advertising information
Would you like to advertise in Cell Cycle?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Cell Cycle.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors